Insufficient use of mineralocorticoid receptor antagonists in patients that underwent renal sympathetic denervation for resistant hypertension

摘要

The prevalence of hypertension appears to be around 30-54% of the general population but only one third of the patients are under control. Hypertension is defined as resistant to treatment when a therapeutic strategy that includes appropiate lifestyle measures plus a diuretic and two other antihypertensive drugs belonging to different classes at adequate doses. It is assosiated with high risk of cardiovascular morbidity and mortality. Denervation of renal sympathetic nerves with radiofrequency ablation catheter is a new non-drug, therapeutic approach in the treatment of resistant hypertension (RH) [1 ]. Recent guidelines for the management of arterial hypertension addressed renal sympathetic denervation (RSD) as a Class lib recommendation for the patients with truly RH (clinic BP > 160/ 110 mm Hg confirmed by ambulatory BP monitoring) [1,2